A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs LY 3127760 (Primary) ; Celecoxib
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Apr 2014 according to ClinicalTrials.gov record.
- 19 Nov 2013 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.